AGM/EGMJun 3, 2026, 08:01 AM
NewAmsterdam Pharma Shareholders Approve ESPP & AGM Proposals
AI Summary
NewAmsterdam Pharma Co N.V. held its 2026 Annual General Meeting, where shareholders approved the 2026 Employee Stock Purchase Plan (ESPP). The ESPP allows eligible employees to purchase up to 1,150,000 ordinary shares at a 15% discount. Additionally, shareholders approved the 2025 annual accounts, discharged directors from liability, appointed Deloitte Accountants B.V. as auditor, re-appointed two non-executive directors, and extended the Board's authorization to issue ordinary shares until June 2, 2031.
Key Highlights
- Shareholders approved the 2026 Employee Stock Purchase Plan (ESPP) on June 2, 2026.
- The ESPP allows eligible employees to purchase ordinary shares at a 15% discount.
- A maximum of 1,150,000 ordinary shares may be issued under the ESPP, which terminates June 2, 2036.
- Shareholders adopted the 2025 Dutch statutory annual accounts with 91,484,326 votes For.
- Discharge from liability for 2025 directors was approved with 85,229,605 votes For.
- Deloitte Accountants B.V. was approved as external auditor for 2026 and ratified as independent accounting firm.
- John W. Smither and Janneke van der Kamp were re-appointed as non-executive directors.
- Authorization for the Board to issue Ordinary Shares was extended for five years until June 2, 2031.
Price Impact
More from NAMS